<DOC>
	<DOCNO>NCT01161511</DOCNO>
	<brief_summary>This open-label , multi-dose , single-arm , Phase 1 , dose-escalation study XmAb5574 . The study conduct identify maximum tolerate dose ( MTD ) and/or recommend dose ( ) ( RD ) study , characterize safety tolerability , characterize PK , PD immunogenicity , evaluate preliminary antitumor activity XmAb5574 patient relapse refractory CLL/SLL .</brief_summary>
	<brief_title>Safety Tolerability XmAbÂ®5574 Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>relapsed refractory CLL/SLL least 18 year age able receive outpatient treatment followup treat institution complete CLL therapy &gt; 4 week prior first study dose previously treat antiCD19 antibody therapy undergone prior allogeneic stem cell transplantation within 6 month active graft versus host disease active Richter 's syndrome designate Class III IV New York Heart Association ( NYHA ) criteria history myocardial infarction stroke within last 6 month active viral , bacterial , systemic fungal infection require treatment HIV Hepatitis C positive Hepatitis B infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
	<keyword>CD19</keyword>
</DOC>